Is Haemonetics Corp (HAE) Holding Up Well Over a Long-Time Horizon?

At the time of writing, Haemonetics Corp [HAE] stock is trading at $52.23, down -0.46%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HAE shares have lost -31.38% over the last week, with a monthly amount drifted -31.87%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Haemonetics Corp [NYSE: HAE] stock has seen the most recent analyst activity on August 11, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $78 for it. Previously, Barrington Research reaffirmed its Outperform rating on August 08, 2025, and dropped its price target to $86. On August 08, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $62 on the stock. Citigroup upgraded its rating to a Buy but stick to its price target of $90 on July 09, 2025. Robert W. Baird initiated its recommendation with a Outperform and recommended $87 as its price target on June 26, 2025. BofA Securities downgraded its rating to Underperform for this stock on February 07, 2025, and downed its price target to $68. In a note dated December 06, 2024, JP Morgan initiated an Overweight rating and provided a target price of $116 on this stock.

For the past year, the stock price of Haemonetics Corp fluctuated between $52.29 and $94.99. Currently, Wall Street analysts expect the stock to reach $68 within the next 12 months. Haemonetics Corp [NYSE: HAE] shares were valued at $52.23 at the most recent close of the market. An investor can expect a potential return of 30.19% based on the average HAE price forecast.

Analyzing the HAE fundamentals

According to Haemonetics Corp [NYSE:HAE], the company’s sales were 1.35B for trailing twelve months, which represents an -4.40% plunge. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.19 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.39.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 50.83 points at the first support level, and at 49.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 53.48, and for the 2nd resistance point, it is at 54.73.

Ratios To Look Out For

It is important to note that Haemonetics Corp [NYSE:HAE] has a current ratio of 1.72. Further, the Quick Ratio stands at 1.04, while the Cash Ratio is 0.55. Considering the valuation of this stock, the price to sales ratio is 1.87, the price to book ratio is 2.85 and price to earnings (TTM) ratio is 15.94.

Transactions by insiders

Recent insider trading involved Llorens Josep, Former Officer, that happened on Jun 26 ’25 when 18630.0 shares were purchased. Former Officer, Strong Stewart W completed a deal on Jun 12 ’25 to buy 708.0 shares. Meanwhile, Officer Strong Stewart W bought 7705.0 shares on Jun 04 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.